Effect of octreotide on endometriosis in acromegaly: Case report with review of literature

Seerat Singh, Aditi Anupam Chakravarty, Smita Manchanda¹, Renuka Mallik², Shweta Chopra, Ajay Ajmani³, Bindu Kulshreshtha

Departments of Endocrinology, ¹Radiology, ²Obstetrics and Gynecology, Dr. Ram Manohar Lohia Hospital, ³Department of Endocrinology, BL Kapoor Memorial Hospital, New Delhi, India

ABSTRACT

Objective: To study the effect of octreotide therapy on endometriotic lesions in a patient with coexisting endometriosis and acromegaly. Intervention: Patient: A 34-year-old female was diagnosed with acromegaly and coexisting endometriosis. Post-surgical resection of the tumor, patient was initiated on octreotide therapy. Results: There was improvement in menstrual bleeding as IGF1 levels decreased with Octreotide therapy. Resolution of the endometriotic lesions was observed during follow up. Conclusion: In this unusual case, the treatment of acromegaly concurred with regression in the endometriotic lesions. Causal or incidental association cannot be inferred from the present case.

Key words: Acromegaly, endometriosis, octreotide, remission of endometriosis

INTRODUCTION

The hypothalamo-pituitary ovarian axis is commonly affected in patients with acromegaly. The various gonadal dysfunctions range from oligo-menorrhea, infertility to menopausal symptoms including hot flushes and vaginal atrophy.[1-3] Uncommonly, acromegalic females may present with features of PCOS i.e. hirsuitism, menstrual disturbances and polycystic ovaries.[4] Causes of ovarian dysfunction in these patients include hyperprolactinemia, gonadotropin dysfunction due to pituitary mass effect and direct or indirect effect of Growth Hormone (through Insulin like Growth factors) on ovaries.[5] Endometriosis is a chronic and recurrent disease characterized by the presence and proliferation of endometrial tissue outside the uterine cavity, which occurs in approximately 10% of women of reproductive age.[6] This is estrogen dependent disorder, whereby lesions respond to inhibition of gonadotropin pulses by GNRH analogues or decrease in estrogen production by aromatase inhibitors.[6-9]

To the best of our knowledge, this condition has never been reported in patients with acromegaly earlier. We report a case of a 34 year old female, with endometriosis who was diagnosed with a GH secreting tumor. The endometrial lesions gradually regressed over time as the acromegaly was treated. The possible reasons for this are discussed.

CASE REPORT

A 34-year-old female presented in the gynaecology outpatient department with complaints of menorrhagia and passage of clots along with abdominal pain which she had been experiencing for the last 13 years. Periods had been regular otherwise, lasting for about 5-6 days each month. USG pelvis revealed bilateral complex cystic adnexal masses with diffuse low level internal echoes. The left adnexal cyst was larger (6.5 × 6.0 cm) and multiloculated. The right adnexal cyst was unilocular and of size 3.5 × 2.8 cm [Figure 1]. MRI pelvis was done subsequently which revealed bilateral cysts, hyperintense on T1 and T1 fat suppressed images and hypointense with
few hyperintense areas (shading) on T2WI and a diagnosis of endometriotic cysts was made [Figure 2a and b]. She was advised to take oral contraceptives and NSAIDS. There was however no change in either the menstrual flow or clots with this therapy. She discontinued the therapy after two months.

Three months later, she approached the doctor with additional complaints of diplopia and left sided temporal hemianopia. MRI brain was done, this revealed a pituitary macroadenoma. She was then referred to the department of Endocrinology for further assessment and management of macroadenoma. History and clinical features were suggestive of acromegaly. Post glucose load Growth Hormone levels were high (39.8 ng/ml). Prolactin levels were 70 ng/ml and free T4 levels were low (freeT4-0.60 ug/dl (0.6-2.2), TSH-4.410 mIU/ml). Thyroxine supplementation was initiated. The patient underwent pituitary surgery, five months following which she underwent 25 sessions of radiotherapy (SRT). Menstrual problems persisted and she underwent dilatation and curettage followed by biopsy of the endometrium which was suggestive of endometrial hyperplasia.

As her IGF-1 levels were high even nine months post operatively, the patient was put on Injection Octreotide. (IGF1-710:Nomalrange 117-329 µg/L). Six months from the introduction of octreotide, the patient developed gallstones. During this period, the patient’s menstrual flow had decreased from 5 to 3 days and there was a reduction in the amount of clots. Follow up ultrasound scans revealed a significant decrease in the size of the lesions over a period of one year with bilateral normal ovaries in the scans done at three years and subsequently [Figure 3]. She was continued on monthly octreotide injections. There was a gradual decline and normalisation of IGF-1 levels over a period of three years with this treatment [Table 1]. Octreotide therapy was stopped after four years. Concurrently, there was a gradual improvement and normalisation of menstrual flow and pattern. Ultrasonography revealed bilateral normal ovaries. Presently, the patient is amenorrhoeic for the past 3 years. Hormonal profile was suggestive of hypogonadotropichypogonadism (LH-1.84 mIU/ml normal value range 0.8-15.5 mIU/ml in fertile females age group, FSH-7.03 mIU/ml normal value range 1.3-23.4 mIU/ml, E2-3.00 pmol/L (97.5-592 pmol/L), Progesterone -0.052 (0.44-6.47 nmol/L), Prl-15.2 ng/ml, normal value range 3-18.6 ng/ml.

**Discussion**

Endometriosis is a gynaecological disease with endometrial tissues growing at extra uterine sites, most commonly ovaries, other sites being pelvic peritoneum, vagina, bowel, pericardium, sites of previous surgical incisions and least commonly lungs and pleura. Signs and symptoms may range from dysmenorrhea, pelvic pain to infertility. It usually occurs during the reproductive age and prolonged periods of unopposed estrogen and fewer pregnancies may predispose women to endometriosis. The symptoms and lesions of endometriosis regress with reduction of estrogen levels as in surgical, hormonal or natural menopause. An increased risk (5-8%) amongst the first degree relatives, an

---

**Figure 1:** TAS shows bilateral complex cystic adnexal masses with diffuse low level internal echoes. Left adnexal cyst is larger and multiiloculated

**Figure 2:** (a) Coronal T1 fat suppressed MR image shows bilateral homogenously hyperintense adnexal masses. (b) Axial T2WI reveals ‘shading’ characteristic of endometriotic cysts

**Figure 3:** USG pelvis (4 years post octreotide initiation) shows normal bilateral ovaries with no adnexal mass
earlier age of onset for familial versus non-familial cases points towards a polygenic mode of inheritance of this disease. Though the exact cause of endometriosis is not known, there are various hypotheses postulated. Some of the proposed hypotheses include-Retrograde menses theory of Sampson, Coelomic metaplasia theory and Mullerian embryonic rest theory. Dysregulation of a number of genes including aromatase, progesterone receptor and angiogenic factors has been shown in some studies. Growth factors have also been implicated in pathogenesis of endometriosis by promoting endometriolar proliferation and differentiation. A key enzyme in estrogen synthesis, aromatase, has also been found to have abundant and abnormal expression in endometriotic lesions.

Various kinds of remedies have been tried in the treatment of endometriosis. While managing the disease by hormonal interventions helps alleviate the pain, surgical management is known to address the infertility issues better. Frequently used medical treatment modalities for endometriosis include combined contraceptive pills, long acting progestins, GnRH agonists and aromatase inhibitors. These agents lead to relief by inhibition of ovulation and minimization of menstrual blood flow and volume. These agents bring respite and regression of the lesions in 70-90% patients whereas around 10-30% patients may show recurrence if the therapy is stopped. Growth factors have been implicated in the pathogenesis of endometriosis, however, to the best of our knowledge there has been no reported case of endometriosis and acromegaly occurring concurrently. In vitro studies have revealed Insulin like growth factors, TGF-beta, PDGF, beta-FGF and EGF to be potent mitogens for endometriolar stromal cells. Annunziata et al. studied the effect of JV-1-36, a GHRH antagonist on proliferation and survival of primary ectopic human endometriolar stromal cell (HESC). The HESC proliferation was studied by 955. Surgery 10.29 started Octreotide 2.29. Ultrasonography evidence 1.67 started Octreotide at 3 months 7 months continued Octreotide stopped at 3 months 6 months continued Octreotide at 2 years 1 month. OCTREOTIDE continued continued octreotide started Octreotide at 3 years 1 month continued Octreotide at 3 years 7 months continued Octreotide at 4 years 6 months continued Octreotide stopped. Growth factors have also been implicated in pathological regression of endometriosis as the patient developed hypogonadal status. While regression of endometriosis with development of a hypogonadal status is well known, such an improvement in the symptoms or lesions with a decrease in IGF1 levels has not been described earlier.

### Table 1: Radiological and hormonal parameters while on follow up

| Date       | IGF 1 (µg/L) | Growth hormone (µg/L) | Treatment         | MRI                                                                 | Ultrasonography evidence                                      |
|------------|--------------|-----------------------|-------------------|----------------------------------------------------------------------|---------------------------------------------------------------|
| Basal      | 955          | 39.8                  | Surgery           | uterus normal Rtovary 3.1×2.8 cm Lt ovary 6.5×6.0                     | Complex cystic adnexal masses with diffuse low level internal echoes. Left adnexal cyst is larger and multiloculated |
| At one year| 305          | 1.67                  | Octreotide started | Posterior wall uterine fibroid. Bilateral ovarian cysts measuring 22 mm each suggestive of endometriosis 2.3×2.2 cm Posterior wall uterine fibroid. Bulky ovaries but cysts not seen. Rt ovary 10 cc; Lt ovary 14.4 cc |
| At 2 year 1 month | 476          | 2.29                  | Octreotide continued | Posterior wall uterine fibroid. Bilateral ovarian cysts measuring 22 mm each suggestive of endometriosis 2.3×2.2 cm Posterior wall uterine fibroid. Bulky ovaries but cysts not seen. Rt ovary 10 cc; Lt ovary 14.4 cc |
| At 2 year 7 months | 396          | -                     | Octreotide continued | Posterior wall uterine fibroid. Bilateral ovarian cysts measuring 22 mm each suggestive of endometriosis 2.3×2.2 cm Posterior wall uterine fibroid. Bulky ovaries but cysts not seen. Rt ovary 10 cc; Lt ovary 14.4 cc |
| At 3 years 1 months | 136          | -                     | Octreotide continued | Posterior wall uterine fibroid. Bilateral ovarian cysts measuring 22 mm each suggestive of endometriosis 2.3×2.2 cm Posterior wall uterine fibroid. Bulky ovaries but cysts not seen. Rt ovary 10 cc; Lt ovary 14.4 cc |
| At 3 years 7 months | 200          | -                     | Octreotide continued | Posterior wall uterine fibroid. Bilateral ovarian cysts measuring 22 mm each suggestive of endometriosis 2.3×2.2 cm Posterior wall uterine fibroid. Bulky ovaries but cysts not seen. Rt ovary 10 cc; Lt ovary 14.4 cc |
| At 4 years 6 months | 172          | 0.24                  | Octreotide stopped | Posterior wall uterine fibroid. Bilateral ovarian cysts measuring 22 mm each suggestive of endometriosis 2.3×2.2 cm Posterior wall uterine fibroid. Bilateral ovarian cysts measuring 22 mm each suggestive of endometriosis 2.3×2.2 cm |

In conclusion, this was a rare case report where endometriosis and acromegaly coexisted. The treatment of acromegaly concurred with regression in the endometriotic lesions.

### References

1. Melmed S. Acromegaly. In: Degroot LJ, Jameson JL, editors. Endocrinology. 5th ed., vol. 3. Philadelphia: WB Saunders; 2006.
2. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992;21:597-614.
3. Duncan E, Wass JA. Investigation protocol: Acromegaly and its investigation. Clin Endocrinol (Oxf) 1999;50:285-93.
4. Kaltsas GA, Androulakis II, Tziveriotis K, Papadogias D, Tsikini A, Makras P et al. Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clin Endocrinol (Oxf) 2007;67:917-22.
5. Lilian M, Guidice LC. Endometriosis. In: LJ Degroot, JL Jameson, editors. Endocrinology. 5th ed., vol. 1. Philadelphia: WB Saunders; 2006.
6. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1995;60:75-9.

7. Allawadi RK, Jobanputra S, Kataia M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: A pilot study. Fertil Steril 2004;81:290-6.

8. Simpson JL, Elias S, Malinak LR, Buttram VC Jr. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 1980;137:327-31.

9. Moen MH, Magnus P. The familial risk of endometriosis. Acta Obstet Gynecol Scand 1993;72:560-4.

10. Kennedy S, Hadfield R, Mardon H, Barlow D. Age of onset of pain symptoms in non-twin sisters concordant for endometriosis. Hum Reprod 1996;11:403-5.

11. Lamb K, Hoffmann RG, Nichols TR. Family trait analysis: A case-control study of 43 women with endometriosis and their best friends. Am J Obstet Gynecol 1986;154:596-601.

12. Gravenwald P. Origin of endometriosis from mesenchyme of coelomic walls. Am J Obstet Gynecol 1942;44:470-4.

13. Kao LC, Germeyer A, Tulac S, Lobo S, Yang JP, Taylor RN, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology 2003;144:2870-81.

14. Giudice LC, Dsupin BA, Gargosky SE, Rosenfeld RG, Irwin JC. The insulin-like growth factor system in human peritoneal fluid: Its effects on endometrial stromal cells and its potential relevance to endometriosis. J Clin Endocrinol Metab 1994;79:1284-93.

15. Sbracia M, Zupi E, Alo P, Manna C, Marconi D, Scarpellini F, et al. Differential expression of IGF-I and IGF-II in eutopic and ectopic endometria of women with endometriosis and in women without endometriosis. Am J Reprod Immunol 1997;37:326-9.

16. Chang SY, Ho YS. Immunohistochemical analysis of insulin-like growth factor I, insulin-like growth factor I receptor and insulin-like growth factor II in endometriotic tissue and endometrium. Acta Obstet Gynecol Scand 1997;76:112-7.

17. Zeitoun KM, Bulun SE. Aromatase: A key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999;72:961-9.

18. Lall Seal S, Kamily G, Mukherji J, De A, Ghosh D, Majhi AK. Aromatase inhibitors in recurrent ovarian endometriomas: Report of five cases with literature review. Fertil Steril 2011;95:291.e15-8.

19. Crosignani P, Olive D, Bengquist A, Luciano A. Advances in the management of endometriosis: An update for clinicians. Hum Reprod Update 2006;12:179-89.

20. Diwadkar GB, Falcone T. Surgical management of pain and infertility secondary to endometriosis. Semin Reprod Med 2011;29:124-9.

21. Hughes EG, Fedorkow DM, Collins JA. A quantitative overview of controlled trials in endometriosis-associated infertility. Fertil Steril 1993;59:963-70.

22. Adamson GD, Pasta DJ. Surgical treatment of endometriosis-associated infertility: Meta-analysis compared with survival analysis. Am J Obstet Gynecol 1994;171:1488-504; discussion 1504-5.

23. Dlugi AM, Miller JD, Krittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study. Lupron Study Group. Fertil Steril 1990;54:419-27.

24. Mahmood TA, Templeton A. The impact of treatment on the natural history of endometriosis. Hum Reprod 1990;5:965-70.

25. Fedele L, Bianchi S, Bocciolone L, Di Nola G, Franchi D. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: A controlled study. Fertil Steril 1993;59:516-21.

26. Huang JC, Papasakelarious C, Dawood MY. Epidermal growth factor and basic fibroblast growth factor in peritoneal fluid of women with endometriosis. Fertil Steril 1996;65:931-4.

27. De Leon FD, Vijayakumar R, Brown M, Rao CV, Yussman MA, Schultz G. Peritoneal fluid volume, estrogen, progesterone, prostaglandin, and epidermal growth factor concentrations in patients with and without endometriosis. Obstet Gynecol 1986;68:189-94.

28. Anunziata M, Grande C, Scarlatti F, Deltetto F, Delpiano E, Camanni M, et al. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line. Fertil Steril 2010;94:841-9.

Cite this article as: Singh S, Chakravarty AA, Manchanda S, Mallik R, Chopra S, Ajmani A, Kulshreshtha B. Effect of octreotide on endometriosis in acromegaly: Case report with review of literature. Indian J Endocr Metab 2014;18:241-4.

Source of Support: Nil, Conflict of Interest: None declared.